Overview

A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are to: - Evaluate the potential effects of PPI-668 at steady state on the pharmacokinetic (PK) profile of midazolam following a single oral dose in human subjects. - Evaluate the potential effects of PPI-668 at steady state on the PK profile of omeprazole following a single oral dose in human subject
Phase:
Phase 1
Details
Lead Sponsor:
Presidio Pharmaceuticals, Inc.
Treatments:
Midazolam
Omeprazole